Singapore, Mar 08, 2010: Solasia Pharma, a developer of oncology pharmaceuticals has signed a license and supply agreement with Kyowa Hakko Kirin that provides Kyowa Hakko Kirin with an exclusive right to market and sell SP-01 (Sancuso) in Taiwan, Hong Kong, Singapore and Malaysia.

Under the terms of the agreement, Solasia will receive upfront, regulatory and sales milestones. Kyowa Hakko Kirin will be responsible for all commercialization activities in Taiwan, Hong Kong, Singapore and Malaysia. Solasia will supply product to Kyowa Hakko Kirin in these territories.

Sancuso is the first and only commercialized extended release granisetron transdermal product. In May 2008, Solasia acquired the exclusive right to Sancuso from ProStrakan Group for Japan, China, and other territories in Asia. Solasia retains full rights in Japan and China where it is currently conducting Sancuso clinical development activities. Sancuso was approved in the United States in September 2008 for the prevention of chemotherapy-induced nausea and vomiting.

“We are very excited to build upon our strong relationship with Kyowa Hakko Kirin, and look forward to seeing Sancuso launched in these Asian territories in the near future,” stated Solasia President Steve Engen.